Evaluation of early prediction using 18F-FDG PET/CT for patients with Iodine-131 refractory differentiated thyroid carcinoma treated with lenvatinib

Evaluation of early prediction using 18F-FDG PET/CT for patients with Iodine-131 refractory differentiated thyroid carcinoma treated with lenvatinib - Early Prediction using 18F-FDG PET/CT for patients with differentiated thyroid carcinoma treated with lenvatinib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022592

Enrollment

Registered

2016-06-06

Start date

2016-06-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid carcinoma

Interventions

18F-FDG PET/CT is supposed to underwent 1 week after initiation of therapy with lenvatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients to be treated with lenvatinib 2) Patients more than 18 years old. 3) Histologically confiremed differentiated thyroid carcinoma 4) Iodine-131 refractory 5) Appropriate physical status 5) Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) Medullary or undifferentiated thyroid carcinoma 2) Ever treated with chemotherapy 3) Double cancer 4) Poor physical status 5) Severe complication 6) Fasting blood glucose over 150 mg/dl 7) Brain metastasis or vascular thrombus requiring treatment 8) Inappropriate to perform 18F-FDG PET/CT or CT due to complications 9) Pregnanant or nursing woman 10) Other inappropriate patients judged byinvestigators

Design outcomes

Primary

Measure	Time frame
Receiver Operating Characteristic-Area Under the Curve obtained by 18-FDG PET/CT performed 1 week after initiation of therapy with lenvatinib compared with conventional CT	—

Countries

Japan

Contacts

Public ContactSatoshi Takeuchi

Hokkaido University Graduate School of Medicine Department of Medical Oncology

stakeuch@med.hokudai.ac.jp011-706-5551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026